Company intelligence / Profile preview

Stemcentrx

South San Francisco, California, United Statesinvestors.abbvie.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Stemcentrx’s lead program, rovalpituzumab tesirine (“Rova-T”), an anti-DLL3 antibody-drug conjugate for SCLC, showed early promise with a reported response rate of up to 44% in high DLL3-expressing patients. However, subsequent clinical development failed to deliver positive results and the program was ultimately discontinued post-acquisition. No products reached commercialization.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

1 asset

rovalpituzumab tesirine

Phase 3

Indications: Small cell lung cancer

Beyond the preview

Go deeper on Stemcentrx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stemcentrx.

Explore the full profile